36
Participants
Start Date
June 1, 2004
Primary Completion Date
August 1, 2012
Study Completion Date
June 1, 2015
Cetuximab
500 mg/m2, IV every two weeks
Oxaliplatin
85 mg/m2, IV, q 2 weeks
Capecitabine
2500 mg, po bid x 7 days every two weeks
Bellevue Hospital, New York
New York University Langone Medical Center, New York
Collaborators (1)
Eli Lilly and Company
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
NYU Langone Health
OTHER